Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.34 - $14.60
Previous CloseN/A
Volume524.53K
Average Volume (3M)1.31M
Market Cap
$543.05M
Enterprise Value$221.32M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.96
Next Earnings
Mar 27, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding44,475,536
10 Day Avg. Volume1,614,153
30 Day Avg. Volume1,311,801
Standard Deviation0.60
R-Squared0.01
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.23
Enterprise Value/Ebitda-4.54
Forecast
1Y Price Target
$19.75Price Target Upside69.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCAN-2409 treatment in a Phase 2a study resulted in a pathological complete response in 93% of biopsies, indicating strong efficacy in patients.
Regulatory ApprovalPositive Phase 3 data for CAN-2409 in prostate cancer supports FDA approval, with a significant reduction in risk for recurrence or death and a high rate of complete responders.
Bears Say
Manufacturing And CommercializationThere are risks to the thesis including the need for significant manufacturing scale for commercialization and the durability of impact not yet proven outside prostate cancer.
---
Ownership Overview
21.05% Insiders
3.26% Mutual Funds
19.59% Other Institutional Investors
50.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $1.34 and its highest was $14.60 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $543.05M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 32 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.33.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 44,475,536 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.33 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.233%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
---
Candel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (69.82% Upside)
$19.75 (69.82% Upside)
Blogger Sentiment
Neutral
CADL Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
560.79%
12-Months-Change
Fundamentals
Return on Equity
-1344.47%
Trailing 12-Months
Asset Growth
-57.02%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.
---
CADL Stock 12 Month Forecast
Average Price Target
$19.75
▲(69.82% Upside)
Technical Analysis
Best Analysts Covering CADL
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+294.17%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +294.17% per trade.
---